ClinicalTrials.gov posted results on 2026-07-31 for pembrolizumab in NCT03108495, a terminated phase 2 study of recurrent, metastatic, or persistent cervical carcinoma. The multicenter trial enrolled 210 participants and evaluated LN-145 alone or with pembrolizumab after lymphodepletion and IL-2.
Background
The study tested adoptive cell therapy with autologous tumor infiltrating lymphocytes, using LN-145 with or without pembrolizumab, also known as Keytruda. The trial focused on participants with cervical carcinoma.
Trial design
This was a prospective, multicenter, multiple-cohort, open-label interventional study. The brief summary says participants received TIL infusion, with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion preparative regimen.
Key results
Posted results included objective response and disease control data across cohorts. For Cohort 1, objective response rate was reported in 15 participants, median duration of response was 6.8 months, disease control rate was 43 participants, and median progression-free survival was 2.8 months. For Cohort 2, objective response rate was reported in 5 participants, median duration of response was 6.7 months, and disease control rate was 23 participants. For Cohort 4, adverse events were reported in 10 participants and efficacy/objective response rate in 2 participants. For Cohort 5, adverse events were reported in 2 participants and efficacy/objective response rate in 0 participants.
What this means
The posted record adds cohort-level outcome data for an investigational cervical cancer cell therapy program that included pembrolizumab as a combination arm. Because the study was terminated, the results should be interpreted as trial data from a discontinued program rather than a completed development pathway.
Source
This information is based on ClinicalTrials.gov trial results for NCT03108495, posted on 2026-07-31. The record is available at clinicaltrials.gov.